Phase 1 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have measurable multiple myeloma disease that can be tracked during the trial, as defined by the trial's guidelines.
- People whose overall health and ability to carry out daily activities meets the trial's requirements — scored as 2 or below on a standard cancer health scale (Arms A and B), or 1 or below (Arms C and D).
- People who have multiple myeloma that has come back or stopped responding to treatment, with confirmed signs of the disease getting worse during or after their most recent treatment.
- People who have never previously been treated with the study drug etentamig (also known as ABBV-383).
- Arm A specifically: People who have received at least 3 prior rounds of treatment, including three specific types of therapy — a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody treatment.
- Arm B specifically: People who have received at least 2 prior rounds of treatment, including a proteasome inhibitor, an immunomodulatory drug, an anti-CD38 antibody treatment, and a previous therapy targeting a protein called BCMA (either an antibody-drug conjugate or a CAR-T cell therapy).
- Arm C specifically: People who have received at least 2 prior rounds of treatment, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody treatment, and who are considered suitable to receive the study drug as an outpatient (without staying in hospital).
- Arm D specifically: People who have received between 1 and 3 prior rounds of treatment, including at least one of — a proteasome inhibitor, an immunomodulatory drug, or an anti-CD38 antibody treatment, and who are considered suitable to receive the study drug as an outpatient.
Who may not be able to join:
- Arm A: People who have previously received any therapy targeting the BCMA protein.
- Arms C and D: People whose disease is considered to be progressing rapidly, as assessed by the treating doctor.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: ABBVIE INC., AbbVie
Phone: 844-663-3742
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Arm A (Part 1 and Part 2) Arm C, and Arm D: Number of Grade >= 2 Cytokine Release Syndrome (CRS) Events; Arm B: Number of Adverse Events (AEs) of Special Interest (CRS and Immune Effector Cell-associated Neurotoxicity Syndrome [ICANS])
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.